Market Overview

UPDATE: Citigroup Raises PT on Cynosure Following 2Q13 Results Report

Share:
Related CYNO
Benzinga's Top Initiations
Cynosure Receives Expanded FDA 510(k) Clearance To Market SculpSure for Non-Invasive Lipolysis of the Abdomen

In a report published Thursday, Citigroup analyst Matthew J. Dodds reiterated a Buy rating on Cynosure (NASDAQ: CYNO), and raised the price target from $36.00 to $41.00.

In the report, Citigroup noted, “2Q13 results were ahead of our and the Street's expectations as the impact of the late quarter close of the PMTI deal was more pronounced than expected. Underlying trends remain healthy and we continue to expect a sizable jump in EPS in 2014 when the combined SG&A is leveraged.”

Cynosure closed on Wednesday at $28.48.

Latest Ratings for CYNO

DateFirmActionFromTo
Aug 2015Stifel NicolausInitiates Coverage onHold
Jun 2015Northland SecuritiesMaintainsOutperform
May 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for CYNO
View the Latest Analyst Ratings

Posted-In: Citigroup Matthew J. DoddsAnalyst Color Price Target Analyst Ratings

 

Related Articles (CYNO)

Get Benzinga's Newsletters